Biotech Execs Speak Out Against Trump’s Immigration Ban; Big Pharma Remains Mostly Silent
Executive Summary
Letter initiated by six CEOs drew 'absolutely overwhelming' response as 163 leaders of primarily small biotech and venture capital firms signed on; tech firms join court fight.
You may also be interested in...
Scientists Marched To Protect NIH Grants, But Where Was Pharma?
Funding from the US National Institutes of Health is a vital source for biomedical research and pharmaceutical pipelines in turn – but biopharma companies have been largely silent on the matter.
Carrots and Stick: Biopharma At The White House
Drug industry executives discuss drug pricing and tax and regulatory reform in a high-profile meeting with President Trump at the White House.
Immigration Ban: BioPharma Response Varies From Silence To Dissent
While PhRMA, BIO and Pfizer had no response to President Trump’s travel order, Allergan and some smaller firms voiced their objections; PhRMA to meet with Trump on Tuesday.